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Abstract
Predicting peptide binding affinity with human leukocyte antigen (HLA) is a crucial step in developing powerful antitumor
vaccine for cancer immunotherapy. Currently available methods work quite well in predicting peptide binding affinity with
HLA alleles such as HLA-A∗0201, HLA-A∗0101, and HLA-B∗0702 in terms of sensitivity and specificity. However, quite a few
types of HLA alleles that are present in the majority of human populations including HLA-A∗0202, HLA-A∗0203, HLA-A∗6802,
HLA-B∗5101, HLA-B∗5301, HLA-B∗5401, and HLA-B∗5701 still cannot be predicted with satisfactory accuracy using currently
available methods. Furthermore, currently the most popularly used methods for predicting peptide binding affinity are
inefficient in identifying neoantigens from a large quantity of whole genome and transcriptome sequencing data. Here we
present a Position Specific Scoring Matrix (PSSM)-based software called PSSMHCpan to accurately and efficiently predict
peptide binding affinity with a broad coverage of HLA class I alleles. We evaluated the performance of PSSMHCpan by
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analyzing 10-fold cross-validation on a training database containing 87 HLA alleles and obtained an average area under
receiver operating characteristic curve (AUC) of 0.94 and accuracy (ACC) of 0.85. In an independent dataset (Peptide
Database of Cancer Immunity) evaluation, PSSMHCpan is substantially better than the popularly used NetMHC-4.0,
NetMHCpan-3.0, PickPocket, Nebula, and SMM with a sensitivity of 0.90, as compared to 0.74, 0.81, 0.77, 0.24, and 0.79. In
addition, PSSMHCpan is more than 197 times faster than NetMHC-4.0, NetMHCpan-3.0, PickPocket, sNebula, and SMM
when predicting neoantigens from 661263 peptides from a breast tumor sample. Finally, we built a neoantigen prediction
pipeline and identified 117 017 neoantigens from 467 cancer samples of various cancers from TCGA. PSSMHCpan is superior
to the currently available methods in predicting peptide binding affinity with a broad coverage of HLA class I alleles.
Keywords: Antitumor vaccine; peptide-HLA binding affinity; PSSMHCpan; neoantigen
Introduction
Cancer immunotherapy has been proven in recent years to be a
promising strategy that enhances the strengths of the immune
system of cancer patients to fight cancer. This strategy exploits
the fact that the surface of cancer cells has a variety of tumor
antigens (i.e., peptides of 8–13 residues in length) coming from
various kinds of mutated proteins cleaved by the proteasomes
intracellular. These peptides are bound to HLA class I allelic spe-
cific molecules, forming peptide-HLA complexes which are pre-
sented to T cell receptors (TCRs). If TCRs can recognize these
peptide-HLA complexes on the surface of cancer cells, cytotoxic
T lymphocytes will destroy cancer cells. Cancer cells are highly
heterogeneous in terms ofmorphological, phonotypical, and ge-
netic profiles. Cancer cells of different tumors and within the
same tumor could present hundreds of different types of pep-
tides. The immune system of cancer patients could only recog-
nize small populations of cancer cells. To enhance the power
of the cytotoxic T lymphocytes to recognize and eradicate as
many cancer cells as possible, one strategy is to vaccinate cancer
patients with complex antitumor peptides. The first step to de-
velop powerful antitumor vaccines is to predict peptide binding
affinity with HLA class I allele.
To predict peptide binding affinity with HLA class I alleles,
four types ofmethods have been developed, including structure-
based methods, machine learning-based methods, PSSM-based
methods [16], and combined methods. The structure-based
methods predict peptide binding affinity calculating the min-
imum free energy of peptide-HLA complex [30], which allows
us to understand the peptide-HLA binding affinity at the struc-
ture level. However, the predicting speed of this type of meth-
ods is extremely slow and inaccurate due to limited number
of available crystal structures [20]. The machine learning-based
methods predict peptide binding affinity by learning a func-
tion that maps a given peptide to areas with binding affinity
based on available known bound peptides (binders). Because
machine learning-based methods can accurately predict pep-
tides with specific HLA alleles such as HLA-A∗0201, HLA-A∗0101,
and HLA-B∗0702 [25, 41], they are frequently used in many stud-
ies [8, 37, 40]. Thus far, many machine learning-based methods
have been developed, including support vector machine-based
method MHC2PRED [15], hidden markov model-based method
S-HMM [26], artificial neural network-based method NetMHC [2,
17], and pan-specific method NetMHCpan [11, 23, 24]. Although
currently available tools can predict a number of HLA class I
allelic coverage with appreciable area under receiver operating
characteristic curve (AUC), they cannot predict with satisfac-
tory accuracy quite a few types of HLA alleles that are present
in the majority of human populations. For example, NetMHC,
ARB, Nebula, sNebula, and SMM achieved only the average pre-
dicted AUC of no more than 0.85 when they were used in
predicting HLA-A∗0202, HLA-A∗0203, HLA-A∗6802, HLA-B∗5101,
HLA-B∗5301, HLA-B∗5401, and HLA-B∗5701 [19, 21, 27]. Further,
these methods are inefficient in predicting a large quantity of
peptides generated from whole genome and transcriptome se-
quencing data because of their nonlinear computation complex-
ity. In contrast, PSSM-based methods predict peptide binding
affinity by building a matrix from a multiple peptide alignment
that represents the motif information (i.e., the binding anchor).
These methods can predict binding affinity fast, because PSSM’s
linear computational complexity is much less complex than
the nonlinear computational complexity of structure-based and
machine learning-based methods. Based on the mechanism of
PSSM, several software packages have been developed such as
PickPocket [42], SVMHC [9], and nHLAPred [5]. However, the pre-
dicting accuracy of this software is not as good as that of ma-
chine learning-based methods [42]. Recently, to predict peptide-
HLA binding affinity more accurately, scientists from several
groups combined different methods to develop new software,
including NetMHCcons [13], IEDB [34], and HLaffy [22]. Although
these combinedmethods indeed have shown a better predictive
performance as compared to individual methods, their predic-
tive accuracy is still not satisfactory, especially in clinical appli-
cations [4]. To develop more effective immunotherapy, it is nec-
essary to develop better software that can more accurately and
efficiently predict peptide binding affinity with a broad coverage
of HLA class I alleles.
Here, we present a novel software called PSSMHCpan that
can predict peptide binding affinity accurately and efficiently.
We designed this software based on the PSSM mechanism and
trained it with a larger database containing 63 519 peptide-HLA
pairs which allow us to allele specifically predict peptide binding
affinity with HLA class I allele. To predict peptide binding affinity
with a broad coverage of HLA class I alleles, we induce a simple
but powerful pan-specific prediction approach based on the sim-
ilarity of HLA protein sequences. We show that PSSMHCpan can
accurately and efficiently predict peptide binding affinity with a
broad HLA class I allelic coverage of at least 87 types in 10-fold
cross-validation, and it performed better than the other 5 soft-
ware packages when evaluated with Peptide Database of Cancer
Immunity dataset. Finally, we built a prediction pipeline to iden-
tify neoantigens in 467 TCGA tumor samples across 10 types of
cancers.
Methods
PSSM is represented as a motif of multiple sequence alignment
result [39]. The basic principle of PSSMHCpan is that peptides
that bind to a specific HLA allele possess the motif informa-
tion that can be studied by PSSM. We propose the PSSMHC-
pan in two novel aspects. Firstly, we construct a comprehensive
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Figure 1: Heat map of HLA protein sequence similarity. The larger the Z-Score,
the more similar of the pair HLA protein sequences. It showed high similarity
between different types of HLA alleles within the same gene locus.
training database and build allele-specific PSSMs for predicting
peptide binding affinity with a characterized HLA class I allele
(with binders in training database). Secondly, we use the sim-
ilarity of HLA sequences to induce a simple but powerful pan-
specific prediction approach based on our hypothesis below, and
predict peptide binding affinity with uncharacterized HLA class
I allele (without binders in training database).
It is well known that peptides on the cell surface are bound
to the floor of the peptide-binding groove that is in the central
region of the α1/α2 heterodimer (a molecule composed of two
nonidentical subunits) of HLA protein sequences [33]. By ana-
lyzing the sequences of HLA proteins, we noticed that HLA pro-
tein sequences are highly similar among different HLA alleles
(Fig. 1), suggesting that peptides bound to similar HLA alleles
have similar binding affinity according to the predictive value of
IC50. Thereby, we hypothesize that since different HLA protein
sequences are similar, the peptide binding affinity with different
HLA alleles should be similar too. Based on this hypothesis and
the PSSMmechanism, we designed the software PSSMHCpan in
the following three steps: PSSM construction, allele-specific pre-
diction, and pan-specific prediction. The flowchart of PSSMHC-
pan is shown in Fig. 2.
PSSM construction
We define PSSM as a matrix of M rows (amino acid; M = 20)
and N columns (length; N = 8 ∼ 25). Each element Pai in the
matrix is the likelihood of a given character (amino acid) at its
position. We calculate the element Pai through the following
function,
Pai = log Fai + ωBGa ,
where Fai denotes the frequency of amino acid a at position i
from the training database; BGa denotes the background fre-
quency of amino acid a from UniProt database [3]; and ω is a
random value (ranging from 0 to 1) generated from Dirichlet dis-
tribution [1].
Peptide
HLA allele
Training database
Characterized
Pan-specific prediction
YES
NO
Similar characterized
HLA alleles and weight
PSSM construction
IEDB IEDBbenchmark MHCBN
IMGT/HLA
Allele-specific
prediction
Characterized HLA
Uncharacterized HLA
HLA similar weight
Candidate binder
(IC50 < 500nM)
BLOSUM62
Example of HLA-A*0201 specific PSSM
Training database
Constructing library of HLA similar weight
Input
Output
Blast
SYFPEITHI
NetMHCpan
HLA distance
Figure 2: Method of PSSMHCpan. The three main steps are shown in grey background.
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Table 1: Summary of training database.
Database IEDB IEDB benchmark SYFPEITHI MHCBN Combined Training database
HLA alleles 166 95 109 103 162 123
Binders 54 272 40930 3329 4070 64 677 63519
Allele-specific prediction
To qualitatively predict peptide binding affinity with character-
ized HLA allele, we define a binding score as the sum of the cor-
responding values of each amino acid of a given peptide at each
position in the corresponding allele-specific PSSM.
binding score =
∑N
i=1 Pai
N
We consider a peptide with binding score > 0 as a binder ac-
cording to the signal prediction of GeneID [10]. The higher bind-
ing score that a peptide has, the higher binding affinity this pep-
tide would have.
We converted a binding score into an IC50 value as follows:
IC50 = 50000
Max− binding score/Max− Min,
where Max and Min denote the maximum and the minimum
values of binding score, respectively. In this study, we assigned
Max as 0.8 and Min as −0.8 based on our experience. According
to the recommendation of IEDB [43], we consider a peptide with
IC50 < 500 nM as a binder and a peptide with IC50 < 50 nM as a
strong binder.
Pan-specific prediction
Firstly, we construct a library of HLA similarweight (button panel
in Fig. 2) that contains pairs of characterized and uncharacter-
ized HLA alleles, and each pair has a weight value. We deter-
mine a pair of characterized and uncharacterized HLA alleles
by using BLOSUM62-based [32] BLAST alignment of HLA pro-
tein sequences and assign the alignment score as the weight
value.We also extracted the nearest distance of HLA alleles from
NetMHCpan-3.0 [23] as a pair of characterized and uncharacter-
ized HLA alleles and assigned a constant as the weight value.
Secondly, we qualitatively predict the binding affinity of a
given peptide with uncharacterized HLA allele with an IC50un
value which is calculated as below:
I C50un =
∑S
i=1(w
∗
i IC50i)
∑S
i=1 wi
,
where S denotes the sum of characterized HLA alleles that pair
up the specific uncharacterized HLA allele according to the li-
brary of HLA similar weight. wi and I C50i denote the weight
value and the allele-specific prediction result of peptide bind-
ing affinity with HLA allele i. We also consider a peptide with
IC50un < 500 nM as a binder, and a peptide with IC50un < 50 nM
as a strong binder.
10-fold cross-validation
We applied 10-fold cross-validation [4] to evaluate the perfor-
mance of peptide-HLA binding prediction as follows. Firstly,
Table 2: Summary of 467 cancer samples from TCGA cohort.
Cancer type Patient no. Cancer type Patient no.
BLCA 19 LIHC 47
BRCA 93 LUAD 57
COAD 16 PRAD 43
HNSC 39 STAD 28
KIRC 67 THCA 58
we randomly partitioned our collected experientially verified
binders (see Data description) into 10 subsets of nearly equal
size. Subsequently, we performed 10 iterations of training and
validation. In each iteration, we use a different subset of data for
validation, while the remaining 9 subsets for training. To evalu-
ate specificity, we also added the nearly same number of non-
binders (see Data description) to our subset of data for valida-
tion. In another word, each validation dataset consist of nearly
equal number of binders and nonbinders.
Data description
We collected our training database of HLA class I binders from
the following resources: the Immune Epitope Database and
Analysis Resource (IEDB) [36], IEDB benchmark [14], SYFPEITHI
[31], MHCBN [6], and in-house experimental epitopes. After fil-
tering out duplications and peptides with abnormal amino acids
which do not or rarely exist naturally, such as B, J, O, U, X, and
Z, we obtained 64677 peptide-HLA pairs that cover 162 HLA alle-
les (Table 1). We selected only HLA alleles that consist of at least
10 binders with a fixed length. Finally, we built 241 PSSMs for
allele-specific prediction of peptides with variable lengths (8 ∼
25 peptides) bound to 123 HLA class I alleles (Additional file 1:
Table S1).
We selected 60530 binders covering 87 HLA class I alleles
from our training database for 10-fold cross-validation. To eval-
uate specificity, we collected 60 102 nonbinders that include ex-
perimentally verified ones from IEDB benchmark [14] and com-
puter randomly constructed ones predicted as nonbinders by
any of the following four methods: PSSMHCpan, NetMHC-4.0,
NetMHCpan-3.0, and PickPocket. We use computer-constructed
nonbinders because currently available experimentally verified
nonbinders that meet our requirement only cover 50 HLA class
I alleles.
We collected 64 uncharacterized HLA class I alleles that can-
not be predicted with NetMHC-4.0 but can be predicted with
NetMHCpan-3.0. We extracted 2064 binders that bind to the 64
uncharacterizedHLA alleles fromour training database and 2057
nonbinders as a Dataset for Pan-specific evaluation (DP).
To construct a library of HLA weight similarity, we collected
690 497 pairs of characterized and uncharacterized HLA class I
alleles from 13957 HLA protein sequences in IMGT/HLA (Release
3.23.0) [29], and 2800 pairs from the nearest distance of HLA al-
leles in NetMHCpan-3.0, respectively. After removing duplica-
tions, we retained 691 031 pairs for pan-specific prediction of
Downloaded from https://academic.oup.com/gigascience/article-abstract/6/5/1/3071702/PSSMHCpan-a-novel-PSSM-based-software-for
by Copenhagen University Library user
on 29 September 2017
PSSMHCpan 5
Va
lu
es
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
ACC AUC
PS
SM
HC
pa
n
Ne
tM
HC
*
Ne
tM
HC
pa
n*
Pic
kP
oc
ke
t*
Ne
bu
la*
sN
eb
ula
*
SM
M*
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
AC
C
PS
SM
HC
pa
n
Ne
tM
HC
Ne
tM
HC
pa
n
Pic
kP
oc
ke
t
Ne
bu
la
sN
eb
ula
SM
M
* ** **
** **
**
1 − Specificity
S
en
si
tiv
ity
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.0 0.2 0.4 0.6 0.8 1.0
PSSMHCpan:0.92
NetMHCpan:0.95
PickPocket:0.95
ACCPSSMHCpan
500nM =0.86
ACCNetMHCpan
500nM =0.75
ACCPickPocket
500nM =0.73
0 5 10 15
0
5
10
15
Pearson's rho = 0.89
P−value < 0.01
PSSMHCpan allele−specific log(IC50)
P
S
S
M
H
C
pa
n 
pa
n−
sp
ec
ifi
c 
lo
g(
IC
50
)
        *Training data for prediction tool software are 
        known to substantially overlap with testing data.
(a)                                                                       (b)
(c)                                                                       (d)
Figure 3: Evaluation on broadHLAallelic coverage. (a) The allele-specific prediction evaluation results showedAUCandACCvalues of PSSMHCpan, and also compared to
NetMHC-4.0, NetMHCpan-3.0, PickPocket, Nebula, sNebula, and SMM. (b) The boxplot of individual ACC of a particular HLA allele with fixed peptide length. Comparison
between PSSMHCpan and the other sixmethodswas performed by using paired t test. “∗” denotes P< 0.05 and “∗∗” denotes P< 0.01. (c) The evaluation results showed by
ROC of PSSMHCpan in pan-specific prediction, NetMHCpan-3.0, and PickPocket. The ACC, sensitivity, and specificity at cutoff of 500 nMwere also shown. (d) Correlation
analysis of peptide-HLA binding affinity result of IC50 value in log2 between allele-specific prediction and pan-specific prediction.
peptide binding affinity with 4896 HLA class I alleles (Additional
file 1: Table S1).
We also collected an independent dataset of binders from the
Peptide Database of Cancer Immunity [35]. From this database,
we selected 285 binders that cover 38 HLA alleles of HLA-A,
HLA-B, and HLA-C. After removing duplications, we retained 273
binders for validation.
To detect pan-cancer neoantigens, we obtained somatic mu-
tations from 467 TCGA tumor samples across 10 cancer types
(Table 2) from GDC data portal (https://gdc-portal.nci.nih.gov/),
and the RSEM gene expression data in these tumors and in their
paired normal tissues from FireBrowse (http://firebrowse.org/).
In addition, we also obtained the RNASeq aligned bam files from
these tumors from dbGAP.
Analyses
Evaluation of peptide binding affinity prediction with a broad HLA
class I allelic coverage
To evaluate the allele-specific prediction accuracy of PSSMHC-
pan with a broad HLA class I allelic coverage, we performed
10-fold cross-validation on training data of 87 HLA class I al-
leles that contain at least 12 binders, and obtained an average
AUC of 0.94 and prediction accuracy ACC (ACC = TP+TNTP+FP+TN+FN ,
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Table 3: Assessments (AUC values) of peptide binding affinity prediction with specific HLA alleles and peptide length by PSSMHCpan, NetMHC,
NetMHCpan, PickPocket, Nebula, sNebula, and SMM.
HLA Length PSSMHCpan NetMHC∗ NetMHCpan∗ PickPocket∗ Nebula∗ sNebula∗ SMM∗
A∗0101 9 0.96 0.98 0.98 0.94 0.82 0.97 0.97
A∗0101 10 0.94 0.98 0.97 0.94 0.69 0.96 0.98
A∗0201 9 0.93 0.94 0.94 0.94 0.88 0.93 0.94
A∗0201 10 0.96 0.96 0.97 0.96 0.94 0.97 0.96
B∗0702 9 0.95 0.97 0.97 0.96 0.81 0.95 0.97
B∗0702 10 0.94 0.98 0.97 0.96 0.80 0.93 0.98
A∗0202 9 0.96 0.99 0.99 0.97 0.53 0.89 0.98
A∗0203 9 0.97 0.98 0.99 0.98 0.85 0.97 0.98
A∗0203 10 0.95 0.98 0.98 0.95 0.53 0.96 0.97
A∗6802 9 0.93 0.98 0.98 0.95 0.80 0.95 0.97
A∗6802 10 0.91 0.96 0.96 0.92 0.78 0.97 0.97
B∗5101 10 0.82 0.89 0.90 0.87 0.72 0.96 0.89
B∗5301 9 0.93 0.98 0.98 0.96 0.55 0.88 0.98
B∗5301 10 0.91 0.97 0.95 0.92 0.69 0.91 0.97
B∗5401 9 0.91 0.98 0.97 0.95 0.51 0.89 0.98
B∗5401 10 0.87 0.97 0.97 0.96 0.53 0.88 0.99
B∗5701 9 0.98 0.99 0.99 0.98 0.94 0.99 0.99
∗Training data are substantially overlapped with validation data.
Table 4: The AUC and SD values in 5 times 10-fold cross-validation.
Time 1 2 3 4 5 SD
PSSMHCpan 0.9405 0.9405 0.9408 0.9405 0.9406 0.0001
where TP, FP, TN, and FN represent true-positive, false-positive,
true-negative, and false-negative) of 0.85 under a cutoff of
500 nM. We then used the same validation data to evaluate six
popularly used software packages: NetMHC-4.0, NetMHCpan-
3.0, PickPocket, Nebula [18], sNebula [19], and SMM [28], respec-
tively. It is worth noting that the training data of these six
software packages are from IEDB, IEDB benchmark, MHCBN,
SYFPEITHI, and so on [2, 18, 19, 23, 28, 42], which are largely
overlapped (>65%) with the validation data in our 10-fold cross-
validation analysis. Despite this substantial overlap (which
will biasedly increase the AUC values for these software), we
found that the AUC values of our PSSMHCpan are slightly
lower than those of NetMHC-4.0 and NetMHCpan-3.0, but higher
than those of PickPocket, Nebula, sNebula, and SMM (Fig. 3a;
Additional file 1: Table S2). By comparing the ACC of each HLA
allele with fixed peptide length among the seven software pack-
ages, we found that the median ACC of PSSMHCpan is sig-
nificantly larger than other software (P < 0.05, paired t test;
Fig. 3b). When looking at the AUC value of specific HLA and
peptide length, PSSMHCpan not only achieved the substantially
results of at least 0.93 in previous good prediction HLA alle-
les such as HLA-A∗0101, HLA-A∗0201, and HLA-B∗0702, but also
performed well in other HLA alleles such as HLA-A∗0202, HLA-
A∗0203, HLA-A∗6802, HLA-B∗5301, HLA-B∗5401, and HLA-B∗5701
(Table 3).
Considering that a one-time 10-fold cross-validation of ran-
domly selection and nonbinders constructionmight produce bi-
ased results, we repeated another five times the 10-fold cross-
validation and found that the standard deviations (SD) of AUC
are ≤0.0001, indicating no bias in the 10-fold cross-validation
(Table 4).
To evaluate pan-specific prediction of PSSMHCpan, we re-
moved peptides in the DP dataset (see Data description) from
our training data and retrained PSSMHCpan. We then pre-
dicted those peptides with PSSMHCpan, and obtained an AUC
of 0.92 and an ACC of 0.86. We also predicted those peptides
with NetMHCpan-3.0 and PickPocket, which gave AUC values of
0.95 and ACC values of 0.75 and 0.73, respectively. It is worth
noting that the peptides that we predicted with PSSMHCpan,
NetMHCpan-3.0, and PickPocket are removed from our training
data but included in the training data of NetMHCpan-3.0 and
PickPocket.
To evaluate the pan-specificity of PSSMHCpan, we compared
the allele-specific prediction with pan-specific prediction of
3408 correctly predicted peptides in DP dataset. We observed
a high correlation between allele-specific and pan-specific pre-
diction (Pearson’s rho = 0.89, P < 0.01; Fig. 3d), suggesting that
our PSSMHCpan can quantitatively predict peptide-HLA binding
affinity with profound accuracy.
Mukherjee et al. (2016) recently published a peptide bind-
ing affinity prediction software HLaffy that was evaluated with
peptides from MHCBN and correctly detected 1179 of 1323
binders (Table 5). To compare the performance of our PSSMHC-
pan with that of HLaffy, we removed the peptides in MHCBN
from our training database and retrained our PSSMHCpan with
the remaining peptides. Because nonbinders are much less than
binders inMHCBN, we only used the binders inMHCBN to evalu-
ate and calculated the prediction accuracy by sensitivity (Sen =
T P
TP+FP ). We found that our PSSMHCpan correctly identified 1309
of 1323 binders (Table 5).
Evaluation of peptide binding affinity predictionwith an independent
dataset
Considering cross-validation might overestimate prediction ac-
curacy, we reevaluated PSSMHCpan, NetMHC-4.0, NetMHCpan-
3.0, PickPocket, Nebula, sNebula, and SMMwith an independent
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Table 5: Comparison of PSSMHCpan with HLaffy. The predic-
tion of HLaffy was performed on webserver (http://proline.
biochem.iisc.ernet.in/HLaffy/).
Allele PSSMHCpan HLaffy
HLA-A∗0201 1.00 0.92
HLA-A∗0203 1.00 0.93
HLA-A∗0206 1.00 0.93
HLA-A∗0301 1.00 0.84
HLA-A∗1101 1.00 0.96
HLA-A∗2402 1.00 0.77
HLA-A∗3301 1.00 0.83
HLA-A∗6801 1.00 0.94
HLA-A∗6802 0.95 0.73
HLA-B∗0702 1.00 0.88
HLA-B∗3501 0.99 0.89
HLA-B∗5301 1.00 0.92
HLA-B∗5401 1.00 0.88
All 0.99 0.90
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Figure 4: The evaluation result of the independent dataset. We denoted IC50 <
500 nM as binder in PSSMHCpan, NetMHC, NetMHCpan, PickPocket, and SMM.
In Nebula prediction, value 1.5 as binder. In sNebula prediction, value 0 as
binder.
dataset that contains 273 nonduplicated experimentally verified
binders from the Peptide Database of Cancer Immunity. Of the
273 binders, 238 are included in our training data. To perform in-
dependent evaluation, we firstly removed the 238 binders from
our training data, and then retrained the PSSMHCpan with the
remaining training data. Together, we identified 268 of 273 (0.98)
binders with seven software packages. Of the 268 binders identi-
fied, PSSMHCpan and sNebula identified (245 and 253) substan-
tially more binders than the other five software packages did
(Fig. 4; Additional file 1: Table S4).
Evaluation of the peptide binding affinity prediction efficiency
As whole genome sequencing and whole exome sequencing of
cancer genome data are rapidly increasing, there is an urgent
need to develop software that can quickly identify neoantigens
from cancer genome data. To compare the efficiency of PSSMHC-
pan, NetMHC-4.0, NetMHCpan-3.0, PickPocket, Nebula, sNebula,
Table 6: The predicting speed (CPU time) of the seven software pack-
ages. The fastest ones were marked in bold.
10-fold Breast tumour
cross- neoantigens
Methods validation prediction
PSSMHCpan 18.40 s 6.34 s
NetMHC-4.0 1056.83 s 13 001.57 s
NetMHCpan-3.0 5371.16 s 103 060.24 s
PickPocket 282.83 s 4839.63 s
Nebula 146.70 s Not done
sNebula 31.04 s 1245.88 s
SMM 222.45 s 5369.36 s
CPU time measured in second(s).
and SMM, we first calculated the predicting speed of 10-fold
cross-validation on a training database with 87 HLA class I al-
leles and found that PSSMHCpan is much faster than the other
six (ranging from 1.7 to 291.9 times faster; Table 6). We then used
each software package to independently predict binding affinity
of 661 263 peptides generated from a breast tumor sample that
contains 3062 somatic mutations with 6 HLA class I alleles. We
found that PSSMHCpan completed the analysis in about 6 sec-
onds. In contrast, NetMHC-4.0 took 3.61 hours, NetMHCpan-3.0
took 28.63 hours, PickPocket took 1.34 hours, sNebula took 0.35
hours, and SMM took 1.49 hours to complete the analysis. Ap-
parently, PSSMHCpan is farmore efficient than othermethods in
detecting neoantigens from a large quantity of sequencing data.
Pan-cancer neoantigens
To identify neoantigens that can be used as candidate markers
to develop antitumor vaccine, we developed a neoantigen pre-
diction pipeline to determine what types of mutated peptides in
cancer cells could be brought to the cell surface by HLAs based
on somatic small mutations (SSMs). To maximize prediction ac-
curacy, we included PSSMHCpan, NetMHC-4.0, NetMHCpan-3.0,
and PickPocket into our pipeline to detect neoantigens in TCGA
tumor samples as follows (Fig. 5a). We first annotated missense
SSMs including single nucleotide variants (SNVs) and insertions
and deletions (InDels) with ANNOVAR [38] to create a list of
tumor-specific peptides (8–13) with an in-house script. After HLA
alleles are predicted with Seq2HLA [7], we predict neoantigens
with PSSMHCpan, NetMHC-4.0, NetMHCpan-3.0, and PickPocket,
respectively. Finally, we selected a list of candidate neoantigens
that met the following conditions: (i) predicting as binders (IC50
< 500 nM) by at least two software packages and taking the me-
dian value of IC50 as final result; (ii) the IC50 value of a given
SNV-derived neoantigen must be smaller than that of its cor-
responding wild-type peptide [12]. Using this pipeline, we an-
alyzed the neoantigens across 10 cancer types from the TCGA
cohort.
In total we identified 117017 candidate neoantigens from 467
TCGA cancer samples. We calculated the number of candidate
neoantigens per SSM in different types of cancer and observed
that STAD, PRAD, and BRCA had the highest neoantigens with
2.54, 1.52, and 1.43 per SNV, respectively (Fig. 5b), whereas the
highest neoantigens per InDel were 2.76, 2.59, and 2.34 in PRAD,
STAD, and KIRC, respectively (Fig. 5c). We also compared the
neoantigen loads (number of candidate neoantigens per sample)
across 10 cancer types and found that STAD, COAD, and BLCA
tumors had the highest neoantigen loads with median values of
302, 182, and 163, while the THCA tumors had a lowest median
neoantigen load of 30 (Fig. 5d).
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Figure 5: Pan-cancer neoantigens. (a) The flow-char of neoantigen prediction pipeline. Software with parameters using in the pipeline are shown in dashed line.
(b) The distribution of neoantigens generated from each SNV across diverse cancers. (c) The distribution of neoantigens generated from each InDel across diverse
cancers. (d) The distribution of neoantigen loads across 10 cancer types. The cancer types are sorted by median value of neoantigen loads. (e) The expression of HLA
class I in tumor and corresponding normal samples.
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On average we identified 251 candidate neoantigens in each
tumor. We then investigated whether the expression level of
HLA class I would be increased in cancer cells to bind neoanti-
gens. Indeed, by looking at themRNAexpression in 467 TCGA tu-
mor samples and their paired normal tissues, we found that the
expression of HLA class I wasmarkedly elevated inmost tumors
(Fig. 5e). Since the amount of candidate neoantigens differs sub-
stantially among different tumors, we examined whether the
number of candidate neoantigens was correlated with HLA class
I expression level in each tumor. However, we found no correla-
tion between the number of candidate neoantigens and the HLA
class I expression levels in tumors (Pearson’s rho = −0.05, P =
0.33).
Discussion
Designing antitumor vaccine requires predicting peptide-HLA
binding affinity with high accuracy. In this article, we have pre-
sented a novel software, PSSMHCpan, that allows us to pre-
dict peptide binding affinity with a broad coverage of HLA
class I alleles. By comparing our PSSMHCpan with NetMHC-
4.0, NetMHCpan-3.0, PickPocket, Nebula, sNebula, and SMM, we
demonstrate that overall our PSSMHCpan is at least as good as
the other six in predicting peptide-HLA binding affinity in terms
of accuracy, and PSSMHCpan is far more efficient in detecting
neoantigens from a large quantity of sequencing data.
In recent years, PSSM-basedmethods to predict peptide-HLA
binding affinity were gradually replaced by machine learning-
based methods that are believed to have reliable accuracy and
larger data prediction capability [20]. However, by comparing our
PSSMHCpanwithmachine learning-basedmethodsNetMHC-4.0
and NetMHCpan-3.0, we show that our PSSMHCpan exhibits a
higher predicting accuracy than NetMHC-4.0 and NetMHCpan-
3.0 as evidenced by the independent dataset evaluation. In
terms of data prediction capability, PSSMHCpan can allele-
specifically and pan-specifically predict peptides that bind to 123
and 4896 HLA class I alleles, respectively, while NetMHC-4.0 and
NetMHCpan-3.0 can predict only 89 and 2924 HLA class I alleles,
respectively. Furthermore, the PSSMHCpan displays more than
2050 and 16255 times higher prediction efficiency as compared
to NetMHC-4.0 and NetMHCpan-3.0 (Table 6).
Practically, we noticed that the size of the training database
appeared to directly affect the prediction accuracy. We believe
that a larger training database could have improved the predic-
tion accuracy of PSSMHCpan. For instance, the PSSMHCpan pre-
diction accuracy ACC in predicting 9mer peptides bind to HLA-
A∗0101 and HLA-B∗5703 are 0.96 and 0.70. Not surprisingly, there
are 813 binders for HLA-A∗0101 and only 25 binders for HLA-
B∗5703, respectively, in our training data.
It is worth noting that PSSMswith fewer training bindersmay
contain more zero elements (i.e., amino acid “X” was never ob-
served at position “Y”), which is represented as random omega
in the formula of “PSSM construction” that could affect the pre-
diction accuracy. We investigated what training binder sizes
have less random omega in PSSMs, and how training binder
sizes could affect prediction accuracy. There are 6784 9mer pep-
tides bound to HLA-A∗0201 in our training database. We ran-
domly selected 678 (10%) binders from the 6784 9mer peptides
for predicting. We then repeatedly predicted peptide binding
affinity of the same 678 binders with PSSMHCpan respectively
trained with increasing sizes of binders with an increment step
of 10, randomly selected from the remaining 6106 binders. We
found that the prediction accuracy was increased as the training
sizes increased, and the prediction accuracy reached a plateau
when the sizes of training binders are >100 (Additional file 1:
Table S5). This suggests that PSSMHCpan trained with fewer
than 100 binders would contain fewer random omegas and have
stable prediction accuracy. There are fewer than 100 training
binders in 145 of 241 PSSMs in our PSSMHCpan. In our 10-fold
cross-validation, PSSMs with fewer than 100 training binders
could have increased or decreased AUC, with a mean value of
0.88 (ranging from 0.5 to 1). In the case of the independent
dataset evaluation, 3 of 273 binders are incorrectly predicted due
to PSSMs with fewer than 100 training binders.
Based on the evaluation results (Fig. 4), we recognized that
none of the available software is perfect and that to maximize
the peptide binding affinity prediction accuracy, it is necessary
to use multiple software packages. We believe that to provide
actionable neoantigens that can be used in cancer immunother-
apy, it requires more efforts to validate the function and im-
munogenicity of the predicted neoantigens experimentally.
In conclusion, our PSSMHCpan can predict peptide binding
affinity with a broad coverage of HLA class I alleles accurately
and farmore efficiently comparedwith the currentlymost popu-
lar peptide binding affinity prediction software. Our PSSMHCpan
can not only help develop personalized antitumor vaccines, but
also has great potential in other aspects of cancer immunother-
apy, including designing dendritic cell vaccines, inducing DC-
CTL, TCR-T, and assessing the PD-1/CTLA4 prognosis.
Availability and requirements
 Project name: PSSMHCpan
 Project home page: https://github.com/BGI2016/PSSMHCpan
 Operating system: Platform independent
 Programming language: Perl
 Other requirements: ActivePerl 5.8
 License: MIT
Availability of supporting data and materials
The supporting data from this study are available in the
PSSMHCpan homepage [44] and further supporting data, includ-
ing snapshots of code, are available in the GigaScience database,
GigaDB [45].
Additional files
Additional file 1. Supplementary tables for supporting the anal-
ysis part.
Additional file Table S1. is the list of HLA class I alleles and
corresponding peptide length for allele-specific and pan-specific
prediction. Table S2 is 10-fold cross-validation results of alleles-
specific prediction of PSSMHCpan, and the same validation on
NetMHC, NetMHCpan, PickPocket, Nebula, sNebula, and SMM.
Table S3 is the pan-specific prediction results. Table S4 is the pre-
diction results of the independent dataset evaluation. Table S5
is the validation results of 9mer peptides bound to HLA-A∗0201.
The first column of “size of training database” represents the
number of binder in training PSSMs.
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